Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 16, 2006

The Institute for Genomic Research, J. Craig Venter Institute, J. Craig Venter Science Foundation Consolidate

  • The boards of directors of the J. Craig Venter Institute (JCVI), The Institute of Genomic Research (TIGR), and the J. Craig Venter Science Foundation (JCVSF) have consolidated these affiliated organizations into one, the J. Craig Venter Institute. The research organization formerly known as JCVI will be renamed The Center for the Advancement of Genomics (TCAG).

    With six buildings, more than 250,000 sq. ft. of lab space, and combined assets of over $200 million, the consolidated JCVI is now one of the largest independent research institutes in the U.S., according to these institutes.

    J. Craig Venter, Ph.D., is named as the chairman and CEO of the new JCVI. TIGR, now a division of the JCVI, will continue to be led by Claire Fraser-Liggett, Ph.D., as president. Eric Eisenstadt, Ph.D., will remain as vp for Research at TIGR. TCAG will be led by Robert Strausberg, Ph.D., with Marv Frazier, Ph.D., maintaining his role as vp of research at TCAG. Both operating divisions will retain their existing research and administrative staff members.

    Total number of employees is 520,392 dedicated to research and 124 of them having doctoral degrees. The new organization also boasts one Nobel Laureate and three members of the National Academy of Sciences.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »